Skip to Content

NIH study finds two doses of HPV vaccine may be as protective as full course

Posted on September 08, 2011

Two doses of the human papillomavirus (HPV) vaccine Cervarix were as effective as the current standard three-dose regimen after four years of follow-up, according to researchers from the National Cancer Institute (NCI), part of the National Institutes of Health, and their colleagues. The results of the study, based on data from a community-based clinical trial of Cervarix in Costa Rica, appeared online Sept.9, 2011, in the Journal of the National Cancer Institute.

News Sources

NCI Press Release: NIH study finds two doses of HPV vaccine may be as protective as full course

The National Cancer Institute (NCI) press release for the study  

NCI Cancer Bulletin: HPV vaccine study in Costa Rica yields insights on cancer prevention

News article in NCI's bi-weekly newsletter the Cancer Bulletin

DCEG Linkage: Efficacy of fewer than three doses of HPV vaccine

Feature article in the DCEG Linkage Newsletter

Information for Journalists

To request an interview with a DCEG investigator, contact the NCI Office of Media Relations:

E-mail:
ncipressofficers@mail.nih.gov

Phone: 301-496-6641